MedChemComm · 2017 · 28 citations · 27 references
PharmacyChemistryMedicinal ChemistryBioisosterismDrug DesignOrganic ChemistryBioisosteric DesignBioisosteric ReplacementClassical BioisosteresCovalent Drug DesignCovalent Inhibitor DesignEnzyme InhibitionAcyclic BioisosteresChemical Synthesis Of AnaloguesCovalent InhibitorsIrreversible Covalent InhibitorsTargeted Covalent Inhibitors
, which is about 30-fold higher than that of osimertinib. Taken together, our data suggest that the allenamide-containing compounds inhibited EGFR kinases through covalent modifications. Our study indicates that the allenamide group could serve as an alternative electrophilic warhead in the design of targeted covalent inhibitors, and this bioisostere replacement may have broad applications in medicinal chemistry.
27
Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +11
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
Dick de Zeeuw, Tadao Akizawa, Paul Audhya et al. · New England Journal of Medicine · 2013 · 994 citations · Full text
M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text
Medicine, Oncology, Pharmacology +15